Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 2/20 | 0.49 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | SCD | O00767 | 3/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | RBP4 | P02753 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636016 | 0.87 | P2RX7 (0.50) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL4898713 | 0.82 | HCRTR1 (0.57) | SCD | |
| SCHEMBL4788243 | 0.80 | TSHR (0.53) | CYP2C9CYP2C19MAPK14MGLLCCR5 | |
| SCHEMBL4788064 | 0.80 | TSHR (0.53) | CYP2C9CYP2C19MAPK14MGLLCCR5 | |
| SCHEMBL4238339 | 0.80 | CYP2C9 (0.60) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL3661780 | 0.80 | CYP2C9 (0.60) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL4618974 | 0.79 | CYP2C9 (0.66) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL10304326 | 0.75 | CYP2C9 (0.60) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL4262448 | 0.74 | CYP2C9 (0.63) | CYP2C9CYP2C19HTR2BMAPK14MGLL | |
| SCHEMBL2006284 | 0.74 | CYP2C9 (0.59) | CYP2C9CYP2C19HTR2BMAPK14MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
| EP-1931633-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | Ranbaxy Laboratories Limited (IN) | 2008-06-18 | — | — | EP | disclosed |
| WO-2007029086-A2 | DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS | RANBAXY LABORATORIES LIMITED (IN) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | CYP2C9 1777/4885CYP2C19 2165/4885HTR2B 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.